A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects With Chronic HCV Infection Who Have Received a Liver Transplant
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 03 Aug 2017 Status changed from active, no longer recruiting to completed.
- 28 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
- 28 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Aug 2017.